Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic oleoylethanolamide treatment attenuates diabetes-induced mice encephalopathy by triggering peroxisome proliferator-activated receptor alpha in the hippocampus.
|
31299417 |
2019 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previously, we showed that Krüppel-like factor (KLF)-5 regulates cardiomyocyte PPARα and fatty acid oxidation-related gene expression in diabetes.
|
31029826 |
2019 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activation of PPARα by fenofibrate normalized ECFC/CAC numbers and mitochondrial function in diabetes.
|
31451517 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulation of PPARs genes in the pancreas of diabetic rats after treatment with okra, demonstrates that okra may improve glucose homeostasis and β-cells impairment in diabetes through a PPAR-dependent mechanism.
|
29308616 |
2018 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The gradual impairment of insulin production and signalling in diabetes is associated with elevated plasma fatty acids and increased myocardial free fatty acid uptake and activation of the transcription factor PPARα.
|
28177068 |
2017 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the mechanism for diabetes-induced downregulation of PPARα remains unknown.
|
28270521 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A more renal prominent activation of Wnt signaling was detected both in PPARα<sup>-/-</sup> mice with diabetes or obstructive nephropathy and in PPARα<sup>-/-</sup> tubular cells treated with Wnt3a.
|
27543085 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings indicate that IGFBP-2 might be a new target of metformin action in diabetes and the metformin-AMPK-Sirt1-PPARα-IGFBP-2 network may provide a novel pathway that could be applied to ameliorate metabolic syndromes by controlling IGF-1 bioavailability.
|
27009398 |
2016 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients.
|
24921414 |
2014 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy.
|
23147557 |
2013 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.
|
24113216 |
2013 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
|
23603006 |
2013 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes.
|
23583468 |
2013 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On the other hand, no interaction between diabetes and PPAR +294T/C polymorphism on the risk of ischemic stroke was found (p = 0.089).
|
23512374 |
2013 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, synthetic PPARalpha and PPARgamma ligands are currently used for treating hyperlipidemia and diabetes.
|
19866471 |
2010 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the present study was to identify the association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with diabetes, insulinaemia and insulin resistance.
|
20420754 |
2010 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, PPARA genotype correlated with 5-year mortality in diabetic (22.2% AA vs. 18.8% AG vs. 39.5% GG; P = 0.008), but not non-diabetic (P = 0.96) subjects (genotype by diabetes interaction P = 0.008).
|
20838448 |
2010 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies on the association of the Pro12Ala and C1431T polymorphisms of PPAR? with diabetes and obesity have revealed extensive population-dependent variations.
|
19805902 |
2009 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While candidate gene approaches have not been tremendously successful in identifying relevant genetic contributors to obesity, except PPAR , the advent of genome-wide strategies has recently revealed novel and unexpected genetic factors with strong associations with obesity and/or diabetes, i.e.
|
18230892 |
2008 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the association of single nucleotide polymorphisms (SNPs) of the PPAR-alpha gene (PPARA) with the conversion from impaired glucose tolerance to type 2 diabetes in 767 subjects of the STOP-NIDDM trial in order to investigate the effect of acarbose in comparison with placebo on the prevention of diabetes.
|
17317762 |
2007 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of PPAR activities represents an attractive approach for the treatment of diabetes with associated cardiovascular complications.
|
17157013 |
2007 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a subset of hyperglycemic L1 mice, we observed decreased mRNA expression of AdipoR2 in liver and muscle, as well as decreased peroxisome proliferator-activated receptor (PPAR)alpha target gene expression in liver, raising the possibility that deterioration of adiponectin/AdipoR2 signaling via PPARalpha activation contributes to the progression from compensated insulin resistance to diabetes.
|
17475934 |
2007 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibrates are known to be PPARalpha ligands and were shown to reduce risks of diabetes and cardiovascular disease.
|
17194889 |
2007 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, the PPARalpha haplotype signficantly influenced age at diagnosis (P = 0.027), with the C-L-C and C-V-C haplotypes (intron 1-L162V-intron 7) accelerating onset of diabetes by 5.9 (P = 0.02) and 10 (P = 0.03) years, respectively, as compared with the common A-L-G haplotype, and was associated with an odds ratio for early-onset diabetes (age at diagnosis </=45 years) of 3.75 (95% CI 1.65-8.56, P = 0.002).
|
15677519 |
2005 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Aims of this study were to estimate the allele frequency of the Pro12Ala polymorphism of PPAR gamma2 gene among native Javanese in Indonesia and to investigate the relationship between this polymorphism and obesity or diabetes.
|
15739197 |
2005 |